Clinical Scorecard: Statins Recommended for HIV Patients at Risk for Heart Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | HIV and increased risk for heart disease |
| Key Mechanisms | Statins lower LDL-C and may reduce inflammation associated with HIV. |
| Target Population | Adults with HIV aged 40 to 75 years with a 10-year ASCVD risk of at least 5%. |
| Care Setting | Clinical guidelines for primary prevention of cardiovascular disease. |
Key Highlights
- Statin therapy recommended for HIV patients at risk for ASCVD.
- Pitavastatin reduced major cardiovascular events by 36% in the REPRIEVE trial.
- Moderate-intensity statin therapy recommended for ASCVD risk between 5% and 20%.
- Adverse events included muscle-related symptoms and increased new-onset diabetes.
- First U.S. guideline endorsing statins for primary prevention in HIV patients.
Guideline-Based Recommendations
Diagnosis
- Assess 10-year ASCVD risk in adults with HIV aged 40 to 75 years.
Management
- Initiate moderate-intensity statin therapy for patients with ASCVD risk of 5% or greater.
Monitoring & Follow-up
- Monitor for adverse events, including muscle-related symptoms and diabetes.
Risks
- Potential drug-to-drug interactions with antiretroviral medications.
Patient & Prescribing Data
Adults with HIV on antiretroviral therapy.
Pitavastatin was chosen for its low risk of drug interactions.
Clinical Best Practices
- Engage in clinician–patient discussions for patients with lower ASCVD risk.
- Consider additional HIV-related risk factors when deciding on statin therapy.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
